Tag Archives: Erbitux

Pharma Throws Greece Another Lifeline. Will Greece Reciprocate?

Greece took its part on Wednesday in the latest widespread strikes against austerity measures that swept across Europe, throwing travel networks into disarray and sparking violent clashes between police and workers. But for once Greece wasn’t at the forefront of the misery as the country has been thrown a couple more lifelines — not least […]
Posted in Europe, Global | Also tagged , , , , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. […]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment

Icahn to BMS: Offer is Inadequate

In a statement to the press today, ImClone Chairman Carl Icahn said that the review committee overlooking Bristol-Myers Squibb’s offer to purchase the biotech company for $60 per share $4.5 billion just isn’t good enough. He not only accused BMS of lowballing, but also admitted that the company has been in talks with the head […]
Posted in Biotech, Deals, Strategy | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta